{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:30:31Z","timestamp":1769506231516,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA075115"],"award-info":[{"award-number":["CA075115"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Unchecked growth in three-dimensions (3D) in culture is a key feature of immortalized cells on the path to malignant transformation and hence a potential target phenotype for prevention. Also, expression of genes driving this process, but not that of 2D growth, would likely be more specific to cancer development and their inhibition would be less toxic to normal cells, many of which can grow in 2D but rarely in 3D culture. To define such genes, we compared CRISPR depletion screens performed in HBLAK, a spontaneously immortalized, non-tumorigenic human urothelial cell line, grown in 2D to those in 3D. Using the CRISPR Bassik DTKP (drug target kinase phosphatase) deletion library targeting 2,333 genes, we identified 85 genes which were specifically lost in 3D cultures. Prioritizing hits to those associated with bladder cancer in patients provided us with a set of 11 genes. Only one gene, MAPK1 remained relevant if a human pan-cancer criteria was applied. Single gene in vitro validation confirmed that MAPK1 inhibition was specific to 3D growth. We also found that MAPK1 depletion led to significant growth reductions in human tumor xenografts in vivo. Inhibition of MAPK1 by Ulixertinib, an orally active MAPK1 inhibitor, led to human bladder cancer growth inhibition in both 3D in vitro and in vivo models. In summary, screening for genes specifically driving 3D growth in immortalized cells may provide targets for both prevention and early therapy in bladder and other cancers while potentially limiting therapeutic toxicity.<\/jats:p>","DOI":"10.1038\/s41419-025-07719-5","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T14:54:35Z","timestamp":1749567275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genes driving three-dimensional growth of immortalized cells and cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Mukta","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Fen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-2314","authenticated-orcid":false,"given":"Saravana Kumar","family":"Kailasam Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Duex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Neang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8708-8206","authenticated-orcid":false,"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"7719_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0075-9","volume":"3","author":"HA Loomans-Kropp","year":"2019","unstructured":"Loomans-Kropp HA, Umar A. Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precis Oncol. 2019;3:3.","journal-title":"NPJ Precis Oncol"},{"key":"7719_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc3397","volume":"12","author":"A Umar","year":"2012","unstructured":"Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012;12:835\u201348.","journal-title":"Nat Rev Cancer"},{"key":"7719_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2099-x","volume":"580","author":"K Han","year":"2020","unstructured":"Han K, Pierce SE, Li A, Spees K, Anderson GR, Seoane JA, et al. CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature. 2020;580:136\u201341.","journal-title":"Nature"},{"key":"7719_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.molcel.2020.10.010","volume":"80","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Cho P, Selfors LM, Kuiken HJ, Kaul R, Fujiwara T, et al. 3D culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferroptosis. Molecular Cell. 2020;80:828\u201344. e6.","journal-title":"Molecular Cell"},{"key":"7719_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.stem.2020.02.007","volume":"26","author":"T Ringel","year":"2020","unstructured":"Ringel T, Frey N, Ringnalda F, Janjuha S, Cherkaoui S, Butz S, et al. Genome-scale CRISPR screening in human intestinal organoids identifies drivers of TGF-\u03b2 resistance. Cell Stem Cell. 2020;26:431\u201340.e8.","journal-title":"Cell Stem Cell"},{"key":"7719_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","volume":"41","author":"D Hendriks","year":"2023","unstructured":"Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nat Biotechnol. 2023;41:1567\u201381.","journal-title":"Nat Biotechnol"},{"key":"7719_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.3536","volume":"34","author":"B Evers","year":"2016","unstructured":"Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. 2016;34:631\u20133.","journal-title":"Nat Biotechnol"},{"key":"7719_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nchembio.2050","volume":"12","author":"RM Deans","year":"2016","unstructured":"Deans RM, Morgens DW, \u00d6kesli A, Pillay S, Horlbeck MA, Kampmann M, et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol. 2016;12:361\u20136.","journal-title":"Nat Chem Biol"},{"key":"7719_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"7719_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s10038-017-0376-9","volume":"63","author":"M Kurata","year":"2018","unstructured":"Kurata M, Yamamoto K, Moriarity BS, Kitagawa M, Largaespada DA. CRISPR\/Cas9 library screening for drug target discovery. J Hum Genet. 2018;63:179\u201386.","journal-title":"J Hum Genet"},{"key":"7719_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrrev.2015.01.002","volume":"764","author":"H Shen","year":"2015","unstructured":"Shen H, McHale CM, Smith MT, Zhang L. Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. Mutation Res\/Rev Mutat Res. 2015;764:31\u201342.","journal-title":"Mutation Res\/Rev Mutat Res"},{"key":"7719_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/bs.pmbts.2017.09.003","volume":"152","author":"M Kosicki","year":"2017","unstructured":"Kosicki M, Rajan SS, Lorenzetti FC, Wandall HH, Narimatsu Y, Metzakopian E, et al. Dynamics of indel profiles induced by various CRISPR\/Cas9 delivery methods. Prog Mol Biol Transl Sci. 2017;152:49\u201367.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"7719_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.molcel.2018.11.031","volume":"73","author":"AM Chakrabarti","year":"2019","unstructured":"Chakrabarti AM, Henser-Brownhill T, Monserrat J, Poetsch AR, Luscombe NM, Scaffidi P. Target-specific precision of CRISPR-mediated genome editing. Molecular cell. 2019;73:699\u2013713.e6.","journal-title":"Molecular cell"},{"key":"7719_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15178","volume":"8","author":"DW Morgens","year":"2017","unstructured":"Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nature Commun. 2017;8:15178.","journal-title":"Nature Commun"},{"key":"7719_CR15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nature Genet. 2017;49:1779\u201384.","journal-title":"Nature Genet"},{"key":"7719_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cels.2018.04.011","volume":"6","author":"J Pan","year":"2018","unstructured":"Pan J, Meyers RM, Michel BC, Mashtalir N, Sizemore AE, Wells JN, et al. Interrogation of mammalian protein complex structure, function, and membership using genome-scale fitness screens. Cell Syst. 2018;6:555\u201368.e7.","journal-title":"Cell Syst"},{"key":"7719_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188594","volume":"14","author":"EA Boyle","year":"2018","unstructured":"Boyle EA, Pritchard JK, Greenleaf WJ. High-resolution mapping of cancer cell networks using co-functional interactions. Molecular Syst Biol. 2018;14:e8594.","journal-title":"Molecular Syst Biol"},{"key":"7719_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41588-021-00840-z","volume":"53","author":"M Wainberg","year":"2021","unstructured":"Wainberg M, Kamber RA, Balsubramani A, Meyers RM, Sinnott-Armstrong N, Hornburg D, et al. A genome-wide atlas of co-essential modules assigns function to uncharacterized genes. Nature Genet. 2021;53:638\u201349.","journal-title":"Nature Genet"},{"key":"7719_CR19","first-page":"3237","volume":"31","author":"JW Kim","year":"2011","unstructured":"Kim JW, Ho WJ, Wu BM. The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res. 2011;31:3237\u201345.","journal-title":"Anticancer Res"},{"key":"7719_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110264","volume":"107","author":"JC Fontoura","year":"2020","unstructured":"Fontoura JC, Viezzer C, Dos Santos FG, Ligabue RA, Weinlich R, Puga RD, et al. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. Materials Sci Eng: C. 2020;107:110264.","journal-title":"Materials Sci Eng: C"},{"key":"7719_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/cancers14010190","volume":"14","author":"MA Barbosa","year":"2021","unstructured":"Barbosa MA, Xavier CP, Pereira RF, Petrikait\u0117 V, Vasconcelos MH. 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancers. 2021;14:190.","journal-title":"Cancers"},{"key":"7719_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"7719_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11955-7","volume":"10","author":"J Tycko","year":"2019","unstructured":"Tycko J, Wainberg M, Marinov GK, Ursu O, Hess GT, Ego BK, et al. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements. Nature Commun. 2019;10:4063.","journal-title":"Nature Commun"},{"key":"7719_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3233\/BLC-160065","volume":"2","author":"MJ Hoffmann","year":"2016","unstructured":"Hoffmann MJ, Koutsogiannouli E, Skowron MA, Pinkerneil M, Niegisch G, Brandt A, et al. The new immortalized uroepithelial cell line HBLAK contains defined genetic aberrations typical of early stage urothelial tumors. Bladder Cancer. 2016;2:449\u201363.","journal-title":"Bladder Cancer"},{"key":"7719_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nature Rev Dis Prim. 2023;9:58.","journal-title":"Nature Rev Dis Prim"},{"key":"7719_CR26","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1016\/j.ygeno.2020.09.012","volume":"112","author":"M Basu","year":"2020","unstructured":"Basu M, Ghosh S, Roychowdhury A, Samadder S, Das P, Addya S, et al. Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: Chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway. Genomics. 2020;112:5055\u201365.","journal-title":"Genomics"},{"key":"7719_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/modpathol.2014.81","volume":"28","author":"P Lochhead","year":"2015","unstructured":"Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Modern Pathol. 2015;28:14\u201329.","journal-title":"Modern Pathol"},{"key":"7719_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/BLC-200282","volume":"6","author":"T Strandgaard","year":"2020","unstructured":"Strandgaard T, Nordentoft I, Lamy P, Christensen E, Thomsen MBH, Jensen JB, et al. Mutational analysis of field cancerization in bladder cancer. Bladder Cancer. 2020;6:253\u201364.","journal-title":"Bladder Cancer"},{"key":"7719_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0959-8049(01)00262-3","volume":"37","author":"H-O Adami","year":"2001","unstructured":"Adami H-O, Day N, Trichopoulos D, Willett W. Primary and secondary prevention in the reduction of cancer morbidity and mortality. European J cancer. 2001;37:118\u201327.","journal-title":"European J cancer"},{"key":"7719_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-020-2969-2","volume":"588","author":"X Jin","year":"2020","unstructured":"Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, et al. A metastasis map of human cancer cell lines. Nature. 2020;588:331\u20136.","journal-title":"Nature"},{"key":"7719_CR31","doi-asserted-by":"publisher","first-page":"e1010604","DOI":"10.1371\/journal.pcbi.1010604","volume":"18","author":"M Locard-Paulet","year":"2022","unstructured":"Locard-Paulet M, Palasca O, Jensen LJ. Identifying the genes impacted by cell proliferation in proteomics and transcriptomics studies. PLoS Comput Biol. 2022;18:e1010604.","journal-title":"PLoS Comput Biol"},{"key":"7719_CR32","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1158\/0008-5472.CAN-17-0369","volume":"77","author":"J Li","year":"2017","unstructured":"Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, et al. Explore, visualize, and analyze functional cancer proteomic data using the cancer proteome atlas. Cancer Res. 2017;77:e51\u2013e4.","journal-title":"Cancer Res"},{"key":"7719_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nmeth.2650","volume":"10","author":"J Li","year":"2013","unstructured":"Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013;10:1046\u20137.","journal-title":"Nat Methods"},{"key":"7719_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110735","volume":"109","author":"A Roychowdhury","year":"2023","unstructured":"Roychowdhury A, Pal D, Basu M, Samadder S, Mondal R, Roy A, et al. Promoter methylation and enhanced SKP2 are associated with the downregulation of CDKN1C in cervical squamous cell carcinoma. Cell Signal. 2023;109:110735.","journal-title":"Cell Signal"},{"key":"7719_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-1759(01)00404-5","volume":"254","author":"LJ Jones","year":"2001","unstructured":"Jones LJ, Gray M, Yue ST, Haugland RP, Singer VL. Sensitive determination of cell number using the CyQUANT\u00ae cell proliferation assay. J Immunol Methods. 2001;254:85\u201398.","journal-title":"J Immunol Methods"},{"key":"7719_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jtho.2019.10.009","volume":"15","author":"E Caiola","year":"2020","unstructured":"Caiola E, Iezzi A, Tomanelli M, Bonaldi E, Scagliotti A, Colombo M, et al. LKB1 deficiency renders NSCLC cells sensitive to ERK inhibitors. J Thorac Oncol. 2020;15:360\u201370.","journal-title":"J Thorac Oncol"},{"key":"7719_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0166-2236(89)90040-4","volume":"12","author":"MG Honig","year":"1989","unstructured":"Honig MG, Hume RI. Dil and diO: versatile fluorescent dyes for neuronal labelling and pathway tracing. Trends Neurosci. 1989;12:333\u201341.","journal-title":"Trends Neurosci"},{"key":"7719_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1074\/jbc.M606862200","volume":"282","author":"L-G Yu","year":"2007","unstructured":"Yu L-G, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007;282:773\u201381.","journal-title":"J Biol Chem"},{"key":"7719_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.matbio.2022.04.005","volume":"110","author":"C Huang","year":"2022","unstructured":"Huang C, Sharma A, Thakur R, Rai D, Katiki M, de, et al. Asporin, an extracellular matrix protein, is a beneficial regulator of cardiac remodeling. Matrix Biol. 2022;110:40\u201359.","journal-title":"Matrix Biol"},{"key":"7719_CR40","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1158\/1535-7163.MCT-17-1142","volume":"17","author":"H Jiang","year":"2018","unstructured":"Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, et al. Concurrent HER or PI3K inhibition potentiates the antitumor effect of the ERK inhibitor ulixertinib in preclinical pancreatic cancer models. Mol Cancer Ther. 2018;17:2144\u201355.","journal-title":"Mol Cancer Ther"},{"key":"7719_CR41","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","volume":"16","author":"UA Germann","year":"2017","unstructured":"Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, et al. Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1\/2 inhibitor BVD-523 (ulixertinib). Mol Cancer Ther. 2017;16:2351\u201363.","journal-title":"Mol Cancer Ther"},{"key":"7719_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15:1\u201312.","journal-title":"Genome Biol"},{"key":"7719_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bcp.2018.10.028","volume":"158","author":"N Ji","year":"2018","unstructured":"Ji N, Yang Y, Lei Z-N, Cai C-Y, Wang J-Q, Gupta P, et al. Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance. Biochem Pharmacol. 2018;158:274\u201385.","journal-title":"Biochem Pharmacol"},{"key":"7719_CR44","doi-asserted-by":"publisher","first-page":"16.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3172","volume":"40","author":"ME Burkard","year":"2022","unstructured":"Burkard ME, McKean M, Rodon Ahnert J, Mettu NB, Jones JC, Misleh JG. et al. A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). Am Soc Clin Oncology. 2022;40:16.","journal-title":"Am Soc Clin Oncology."},{"key":"7719_CR45","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","volume":"28","author":"PM Grierson","year":"2023","unstructured":"Grierson PM, Tan B, Pedersen KS, Park H, Suresh R, Amin MA, et al. Phase Ib study of ulixertinib plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2023;28:e115\u2013e23.","journal-title":"Oncologist"},{"key":"7719_CR46","first-page":"10955","volume":"9","author":"W-J Ding","year":"2016","unstructured":"Ding W-J, Tao W-P, Zeng T, Deng J-J, Lei H-B, Ge W. Selective ERK inhibitor ulixertinib inhibits proliferation and induces apoptosis in lymphoma cell lines. Int J Clin Exp Med. 2016;9:10955\u201362.","journal-title":"Int J Clin Exp Med"},{"key":"7719_CR47","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.21.02838","volume":"40","author":"DW Parsons","year":"2022","unstructured":"Parsons DW, Janeway KA, Patton DR, Winter CL, Coffey B, Williams PM, et al. Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute\u2013Children\u2019s Oncology Group Pediatric MATCH trial. J Clin Oncol. 2022;40:2224\u201334.","journal-title":"J Clin Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07719-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:02:52Z","timestamp":1749571372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7719"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07719-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that: All methods performed for this article are in accordance with the relevant guidelines and regulations; all live mice experiments have been performed according to the IACUC protocol (protocol ID: 008253), approved by the Cedars Sinai Medical Center IACUC ethics committee; all human data presented in this article has been obtained from publicly available dataset; no identifiable images of human\/patients have been used in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"442"}}